Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04433546
Other study ID # PB1046-PT-CL-0007
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date July 15, 2020
Est. completion date December 2, 2020

Study information

Verified date December 2020
Source PhaseBio Pharmaceuticals Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death. The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent decision-making and treatment at approximately 20 centers in the United States.


Description:

The study will consist of a Screening/Pre-treatment period, on-site randomization to study treatment. On Day 0 (Visit 2) subjects who meet inclusion criteria and none of exclusion criteria will receive a weekly subcutaneous injection that will continue once weekly until hospital discharge or for a maximum of 4 weeks during hospitalization, whichever is shorter. All subjects will be randomized to either a low control (10 mg), middle (40 mg), or high (100 mg) dose of active treatment. If subject is not discharged, they will continue to Day 7, 14, 21 treatments. Pemziviptadil (PB1046) is expected to improve the clinical outcomes of hospitalized COVID-19 subjects with an earlier hospital discharge and improvement in survival. The duration of hospitalization for each subject will be determined by clinical status independent of study procedures. The estimated duration of the study for each subject, including screening, is approximately 35+7 days. The subjects may be involved up to 42 days.


Recruitment information / eligibility

Status Terminated
Enrollment 54
Est. completion date December 2, 2020
Est. primary completion date December 2, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: 1. Written or witnessed verbal informed consent from patient or remote legal authorized representative (LAR) or remote family member as permitted by governing local or central Institutional Review Board (IRB)/independent Ethic Committee (IEC). 2. Male or female 18-85 years old hospitalized COVID-19 patients (positive local SARS-CoV2 test) 3. Receiving oxygen (O2) by face mask or nasal cannula/prongs and/or with elevated markers of cardiac injury or dysfunction (hsTnI or NT-proBNP) as assessed by local testing Exclusion Criteria: Subjects will be excluded from the study if they meet any of the following criteria: 1. Patients considered unsalvageable or expected to expire within 24 hours 2. On mechanical ventilation or imminent need for mechanical ventilation expected in the next 24 hours 3. Evidence of acute end-organ injury in 2 or more organ systems (not including cardiac or pulmonary), such as, renal, hepatic, or CNS injury 4. Receiving another investigational therapy for treatment or prevention of COVID-19-related hypoxemic respiratory failure or ARDS other than antiviral therapy 5. Systolic blood pressure (SBP) < 95 mmHg and/or diastolic blood pressure (DBP) < 50 mmHg or overt symptomatic hypotension during screening 6. Resting heart rate > 110 BPM (beats per minute) during screening 7. Severe chronic renal failure as measured by the estimated glomerular filtration rate (eGFR) of < 30 mL/min/1.73m2 using the local laboratory calculation of eGFR. 8. Significant liver dysfunction as measured by any one of the following at screening: - ALT (Alanine transaminase) > 3.0 times ULN (upper limit of normal) - AST (Aspartate transaminase) > 3.0 times ULN - Serum bilirubin = 1.6 mg/dL 9. Any in-patient surgical procedure or hospitalization (defined as > 23 hours) within 30 days of subject screening except for prior hospitalization for COVID-19 10. Known hypersensitivity to study drug or any of the excipients of the drug formulation 11. Pregnant or lactating female subjects 12. Any other condition which, in the opinion of the Investigator, would place the subject at increased risk or would preclude obtaining informed consent or confound the objectives of study

Study Design


Related Conditions & MeSH terms

  • Acute Lung Injury
  • Acute Respiratory Distress Syndrome
  • Cardiac Complication
  • Cardiac Dysfunction
  • Cardiac Event
  • Cardiac Failure
  • Cardiac Infarct
  • Clinical Deterioration
  • Coronavirus
  • COVID 19
  • Cytokine Storm
  • Heart Failure
  • Hypoxemic Respiratory Failure
  • Hypoxic Respiratory Failure
  • Inflammation
  • Pneumonia
  • Pulmonary Edema
  • Pulmonary Inflammation
  • Pulmonary Valve Insufficiency
  • Respiratory Complication
  • Respiratory Distress Syndrome, Adult
  • Respiratory Distress Syndrome, Newborn
  • Respiratory Failure
  • Respiratory Insufficiency
  • SARS-CoV-2
  • Syndrome

Intervention

Drug:
Pemziviptadil (PB1046)
Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
Low Dose (10 mg) Control
Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection (10 mg diluted in sodium chloride to match active drug volume)

Locations

Country Name City State
United States Baptist Health Research Institute Jacksonville Florida
United States The University of Kansas Medical Center Kansas City Kansas
United States Sarasota Memorial Hospital Sarasota Florida
United States Adventist Healthcare White Oak Medical Center Silver Spring Maryland

Sponsors (1)

Lead Sponsor Collaborator
PhaseBio Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Impact on invasive hemodynamic parameters as measured by pulmonary artery pressure if patients require right-heart catherization Any time point between injection initiation and Day 35+7
Other Impact on invasive hemodynamic parameters as measured by cardiac output if patients require right-heart catherization Any time point between injection initiation and Day 35+7
Other Incidence of multi-system organ failure (MSOF) Any time point between injection initiation and Day 35+7
Other Number of multi-system organ failure (MSOF) free days Any time point between injection initiation and Day 35+7
Other Number of subjects requiring extracorporeal membrane oxygenation (ECMO) Any time point between injection initiation and Day 35+7
Other Change in circulating ferritin Any time point between injection initiation and Day 35+7
Other Change in circulating D-dimer Any time point between injection initiation and Day 35+7
Other Change in liver function Any time point between injection initiation and Day 35+7
Other Change in other blood chemistry Any time point between injection initiation and Day 35+7
Other Change in hematology Any time point between injection initiation and Day 35+7
Other Change in inflammatory markers Any time point between injection initiation and Day 35+7
Other Change in coagulation markers Any time point between injection initiation and Day 35+7
Other Percent of clinical failure Any time point between injection initiation and Day 35+7
Primary Time to clinical recovery from initiation of pemziviptadil (PB1046) 28 days
Secondary Time to clinical recovery (being well enough for hospital discharge or returning to normal baseline activity level prior to discharge) 28 days
Secondary Time to hospital discharge Any time point between injection initiation and Day 28
Secondary All-cause mortality 28 days
Secondary Reduction in hospital resource utilization defined as a composite of: total days: in hospital, in ICU, on ventilator, on ECMO, with invasive hemodynamic monitoring, with mechanical circulatory support, and with inotropic or vasopressor therapy Composite of: Total hospital days, Total ICU days, Total days of ventilator use, Total days of ECMO, Total days of invasive hemodynamic monitoring, Total days of mechanical circulatory support, Total days of inotropic or vasopressor therapy 28 days
Secondary Time to clinical improvement as defined by reduction of at least 2 points on an 8-category ordinal scale of clinical improvement or discharge from hospital, whichever comes first. Any time point between injection initiation and Day 28
Secondary Change from baseline in cardiac marker troponin I (TrI) Any time point between injection initiation and Day 35+7
Secondary Change from baseline in cardiac marker NT-proBNP/BNP Any time point between injection initiation and Day 35+7
Secondary Change from baseline in TNF alpha Any time point between injection initiation and Day 35+7
Secondary Change from baseline in IL-1 Any time point between injection initiation and Day 35+7
Secondary Change from baseline in IL-6 Any time point between injection initiation and Day 35+7
Secondary Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by clinical adverse events (AEs) and their relationship to pemziviptadil (PB1046). Any time point between injection initiation and Day 35+7
Secondary Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by vital signs and their relationship to pemziviptadil (PB1046) Any time point between injection initiation and Day 35+7
Secondary Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by laboratory results and their relationship to pemziviptadil (PB1046) Any time point between injection initiation and Day 35+7
Secondary Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by electrocardiogram (ECG) abnormalities and their relationship to pemziviptadil (PB1046) Any time point between injection initiation and Day 35+7
Secondary Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by incidence of anti-drug antibodies and their relationship to pemziviptadil (PB1046) Any time point between injection initiation and Day 35+7
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04244474 - Effect of Vitamin D Supplementation on Improvement of Pneumonic Children Phase 1/Phase 2
Completed NCT05815264 - Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above Phase 1
Recruiting NCT04589936 - Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care N/A
Completed NCT02905383 - The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital N/A
Terminated NCT03944551 - Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa N/A
Completed NCT06210737 - A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years Phase 4
Terminated NCT04660084 - Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT05702788 - Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) Phase 2
Not yet recruiting NCT04171674 - Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation. N/A
Active, not recruiting NCT03140163 - Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR] N/A
Completed NCT02638649 - Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
Completed NCT02864420 - Hospitalization at Home: The Acute Care Home Hospital Program for Adults N/A
Recruiting NCT02515565 - Physiotherapy in Patients Hospitalized Due to Pneumonia. N/A
Completed NCT02105298 - Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study) N/A
Completed NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants Phase 1
Completed NCT01416519 - Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation N/A
Completed NCT01399723 - Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia Phase 3
Completed NCT01416506 - Community-Acquired Pneumonia (CAP) Surveillance N/A
Terminated NCT02358642 - Drug to Prevent Pneumonia in the Tube Fed Phase 4